I’m going to take a look at rare diseases from the economic lens of three market failures. Negative Externalities Rare diseases impose significant negative externalities on society and healthcare systems. Consider this statistic – In Europe about 30 million people (1 in 17) suffer from a debilitating rare disease Now take a minute to review…
Tag: Gene Therapy
Gene therapy – Does Health Insurance Penetration Matter?
One of the public policy areas I’m most interested to study is rare diseases. So, today’s question that I’m hoping to answer is – among countries with one or more approved gene therapy drugs, what is the insurance penetration in its population. First step – which countries have an approved gene therapy drug? Here is…